Massachusetts Financial Services’s Ascendis Pharma ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $328M | Buy |
1,901,843
+23,926
| +1% | +$4.13M | 0.1% | 196 |
|
|
2025
Q1 | $293M | Buy |
1,877,917
+10,366
| +0.6% | +$1.62M | 0.1% | 211 |
|
|
2024
Q4 | $257M | Buy |
1,867,551
+565
| +0% | +$77.8K | 0.08% | 234 |
|
|
2024
Q3 | $279M | Buy |
1,866,986
+155,971
| +9% | +$23.3M | 0.08% | 225 |
|
|
2024
Q2 | $233M | Buy |
1,711,015
+93,185
| +6% | +$12.7M | 0.07% | 235 |
|
|
2024
Q1 | $245M | Buy |
1,617,830
+98,611
| +6% | +$14.9M | 0.07% | 237 |
|
|
2023
Q4 | $191M | Buy |
1,519,219
+254,749
| +20% | +$32.1M | 0.06% | 265 |
|
|
2023
Q3 | $118M | Buy |
1,264,470
+176,948
| +16% | +$16.6M | 0.04% | 336 |
|
|
2023
Q2 | $97.1M | Sell |
1,087,522
-270,052
| -20% | -$24.1M | 0.03% | 364 |
|
|
2023
Q1 | $146M | Buy |
1,357,574
+13,972
| +1% | +$1.5M | 0.05% | 294 |
|
|
2022
Q4 | $164M | Buy |
1,343,602
+159,246
| +13% | +$19.4M | 0.06% | 264 |
|
|
2022
Q3 | $122M | Buy |
1,184,356
+349,157
| +42% | +$36.1M | 0.05% | 301 |
|
|
2022
Q2 | $77.6M | Buy |
835,199
+64,270
| +8% | +$5.97M | 0.03% | 390 |
|
|
2022
Q1 | $90.5M | Buy |
770,929
+18,627
| +2% | +$2.19M | 0.03% | 401 |
|
|
2021
Q4 | $101M | Buy |
752,302
+8,323
| +1% | +$1.12M | 0.03% | 397 |
|
|
2021
Q3 | $119M | Buy |
743,979
+43,541
| +6% | +$6.94M | 0.03% | 362 |
|
|
2021
Q2 | $92.1M | Sell |
700,438
-10,607
| -1% | -$1.4M | 0.03% | 410 |
|
|
2021
Q1 | $91.6M | Buy |
711,045
+12,104
| +2% | +$1.56M | 0.03% | 390 |
|
|
2020
Q4 | $117M | Buy |
698,941
+33,184
| +5% | +$5.53M | 0.04% | 342 |
|
|
2020
Q3 | $103M | Buy |
+665,757
| New | +$103M | 0.04% | 320 |
|